GILEAD SCIENCES, INC. 4

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of Gilead common stock at $125.40 per share under a Rule 10b5-1 plan.

On June 15, 2026, Gilead Sciences, Inc. Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of Gilead common stock at a price of $125.40 per share, for total proceeds of approximately $376,200, under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024. Following this transaction, Dickinson directly owns 171,646 shares of Gilead common stock, which, using the reported sale price as a reference, represents an equity stake worth roughly $21.5 million. The sale appears to be a planned diversification or liquidity event rather than an opportunistic trade, given its execution pursuant to the 10b5-1 plan and the modest size relative to his remaining holdings.

Filing Facts

CIK

882095

Ticker

GILD

Form

4

Source Type

sec

Accession

0001310204-26-000020

Alert Tier

8

ATTN Analysis